Genome sequencing identifies a basis for everolimus sensitivity.

@article{Iyer2012GenomeSI,
  title={Genome sequencing identifies a basis for everolimus sensitivity.},
  author={Gopa Iyer and Aphrothiti J. Hanrahan and Matthew Ivan Milowsky and Hikmat A. Al-Ahmadie and Sasinya N. Scott and Manickam Janakiraman and Mono Pirun and Chris Sander and Nicholas D. Socci and Irina Ostrovnaya and Agn{\`e}s Viale and Adriana Heguy and Luke C Peng and Timothy A. Chan and Bernard H. Bochner and Dean F Bajorin and Michael F. Berger and Barry S. Taylor and David B. Solit},
  journal={Science},
  year={2012},
  volume={338 6104},
  pages={
          221
        }
}
Cancer drugs often induce dramatic responses in a small minority of patients. We used whole-genome sequencing to investigate the genetic basis of a durable remission of metastatic bladder cancer in a patient treated with everolimus, a drug that inhibits the mTOR (mammalian target of rapamycin) signaling pathway. Among the somatic mutations was a loss-of-function mutation in TSC1 (tuberous sclerosis complex 1), a regulator of mTOR pathway activation. Targeted sequencing revealed TSC1 mutations… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 299 CITATIONS, ESTIMATED 44% COVERAGE

Molecular Diagnostics in Clinical Oncology

  • Front. Mol. Biosci.
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

mTOR Signaling in Growth, Metabolism, and Disease

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Bladder cancer in the elderly patient: challenges and solutions

  • Clinical interventions in aging
  • 2015
VIEW 15 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

  • The Journal of clinical endocrinology and metabolism
  • 2014
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

mTOR Signaling in Growth, Metabolism, and Disease

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Novel therapeutic targets in advanced urothelial carcinoma.

  • Critical reviews in oncology/hematology
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 12 Highly Influenced Citations

  • Averaged 23 Citations per year from 2017 through 2019